Littisha Lawrance

7PUBLICATIONS
61CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersLiquid biopsiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non-Small Cell Lung Cancer.

|Jan 10, 2026
The Role of Computed Tomography-Determined Total Tumor Volume at Baseline in Predicting Outcomes of Patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.

Elissar Moujaes, Jules Dupont, Littisha Lawrance

|Nov 26, 2024
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases.

Lama Dawi, Younes Belkouchi, Littisha Lawrance

|Jan 31, 2023
Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy.

Younes Belkouchi, Hugues Talbot, Nathalie Lassau

|Jan 21, 2023
Body Composition to Define Prognosis of Cancers Treated by Anti-Angiogenic Drugs.

Pierre Decazes, Samy Ammari, Antoine De Prévia

|Apr 12, 2022
Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion.

Yingping Li, Samy Ammari, Littisha Lawrance

Pageof 2

Frequent Collaborators

6 joint publications

Samy Ammari

4 joint publications

Nathalie Lassau

3 joint publications

Younes Belkouchi

3 joint publications

Hugues Talbot